Sunrise, FL (openPR) 1 October 2010

Bioheart, Inc. – (OTC Bulletin Board: BHRT) a company in the discovery, development and commercialization of autologous cell therapies for targeted treatment of cardiovascular diseases, announced today that the company requires pre-approval from Sea National Bank and Trust for a loan that uses 0000, to refinance the company’s Articles of Association be received? the loan from Bank of America. The loan is for up to completion of definitive documentation and delivery of certificates of deposit Sea of others. The company stated that 7244 loan from Bank of America by a member of the League would be paid? ? The Board of Directors. In return, members will receive shares of common stock and warrants is limited.

About Bioheart, Inc.

Bioheart committed to a leadership position in the cardiovascular industry technology-cells, providing cellular therapies, intelligent devices and biologics to meet the heart failure, lower limb ischemia, ischemic heart failure, acute myocardial infarction and other issues. Bioheart works to prevent the deterioration of the state with monitoring and diagnosis. The company’s articles of association? S aims to regenerate damaged tissue to allow, if possible, and to improve the quality of the lives of patients and health care costs and hospital stays.

specific biotechnology Bioheart on the discovery, development and focused, subject to regulatory approval and commercialization of autologous cell therapies for the treatment of chronic and acute heart damage, and peripheral vascular disease. MyoCell is a clinical cell therapy for muscular derivatives populate regions of scar tissue in a patient’s heart with new living cells for the purpose of improving cardiac function in patients with heart failure.

For more information on Bioheart visit www.bioheartinc.com.

Forward-Looking Statements:

With the exception of historical information are statements in this press release are forward looking and are based on the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limiting the generality of the foregoing, words such as “may,” “will,” “should,” “plan,” “expect,” “believe,” “anticipate,” “intend”, “may,” “would,” continue “estimate” or “” or the negative variations thereof or other similar expressions identify such forward-looking statements.

investors and others are cautioned that a variety of factors, including certain risks, may affect our business and cause actual results to differ materially from those forward-looking statements. These risk factors include, without limitation, (i) our ability to obtain additional financing, (ii) the ability to control and reduce our costs, (iii) our ability to build a distribution network and begin the distribution of certain products for our distribution rights (iv) complete our ability to quickly and successfully purchased our clinical studies, (v) the occurrence of unacceptable side effects during or after preclinical and clinical product candidates, (vi) to obtain the timing and the ability and maintain regulatory approvals for our product candidates (vii) dependence on the success of our lead compound, forecast to (viii) our inability to the extent of our future losses or if or when we are profitable, (ix) the ability to protect our intellectual property rights, and (x) an intensive competition. The Company is also subject to risks and uncertainties in its filings with the Securities and Exchange Commission, including under “Risk Factors” in the Annual Report on Form 10-K for the year ended 31 December 2009 described, and its Quarterly Report on Form 10-Q for the quarter ended 30 June 2010.


Contact

:

Catherine Sulawske Look, COO

954 835 1500

# # #

clear = “all”
Hospital treatment of eating disorders